Tyme Inc. (TYME) Misses Q4 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. HUM
9. CSCO
10. KTOS

Go back to Tyme Inc. (TYME) Misses Q4 EPS by 12c

TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results

May 20, 2020 4:05 PM EDT

TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III registration-intent trial evaluating oral SM-88 as second-line monotherapy for pancreatic cancer TYME & Joseph Ahmed Foundations HopES sarcoma study enrolling patients for the investigator-initiated Phase II trial studying oral SM-88 as maintenance monotherapy in previously treated metastatic Ewings sarcoma and salvage monotherapy in clinically advanced sarcomas TYME to present updated findings from preclinical data on cancer metabolism-based compounds: SM-88 and TYME-18 Strategic... More